MX344704B - Nanopartículas cargadas con medicamento antitumoral quimioterapéutico. - Google Patents

Nanopartículas cargadas con medicamento antitumoral quimioterapéutico.

Info

Publication number
MX344704B
MX344704B MX2013007581A MX2013007581A MX344704B MX 344704 B MX344704 B MX 344704B MX 2013007581 A MX2013007581 A MX 2013007581A MX 2013007581 A MX2013007581 A MX 2013007581A MX 344704 B MX344704 B MX 344704B
Authority
MX
Mexico
Prior art keywords
nanoparticles loaded
chemotherapeutic antitumoral
treatment
chemotherapeutic
antitumoral drug
Prior art date
Application number
MX2013007581A
Other languages
English (en)
Other versions
MX2013007581A (es
Inventor
Pisani Emilia
Lebel-Binay Sophie
Polard Valérie
Original Assignee
Bioalliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma filed Critical Bioalliance Pharma
Publication of MX2013007581A publication Critical patent/MX2013007581A/es
Publication of MX344704B publication Critical patent/MX344704B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los nuevos enfoques terapéuticos para tratar el cáncer, en particular el carcinoma hepatocelular, con nanopartículas cargadas con un agente antitumoral quimioterapéutico. Concretamente, tiene relación con el tratamiento del cáncer mediante la administración de las mencionadas nanopartículas por infusión intravenosa durante al menos dos horas para prevenir los efectos adversos toxicológicos y aumentar la relación beneficio/riesgo del tratamiento.
MX2013007581A 2011-03-31 2012-03-30 Nanopartículas cargadas con medicamento antitumoral quimioterapéutico. MX344704B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305364.9A EP2508207B1 (en) 2011-03-31 2011-03-31 Nanoparticles loaded with chemotherapeutic antitumoral Drug
PCT/EP2012/055756 WO2012131018A1 (en) 2011-03-31 2012-03-30 Nanoparticles loaded with chemotherapeutic antitumoral drug

Publications (2)

Publication Number Publication Date
MX2013007581A MX2013007581A (es) 2013-11-01
MX344704B true MX344704B (es) 2017-01-03

Family

ID=44513370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007581A MX344704B (es) 2011-03-31 2012-03-30 Nanopartículas cargadas con medicamento antitumoral quimioterapéutico.

Country Status (26)

Country Link
US (2) US9763874B2 (es)
EP (2) EP2508207B1 (es)
JP (1) JP5523638B2 (es)
KR (1) KR101578273B1 (es)
CN (2) CN105233301A (es)
AU (1) AU2012233666B2 (es)
BR (1) BR112013019105A2 (es)
CA (1) CA2822177C (es)
CY (1) CY1117868T1 (es)
DK (2) DK2508207T3 (es)
ES (2) ES2424476T3 (es)
HK (1) HK1192841A1 (es)
HR (2) HRP20130702T1 (es)
HU (1) HUE028465T2 (es)
IL (1) IL227466A (es)
ME (1) ME02470B (es)
MX (1) MX344704B (es)
MY (1) MY162339A (es)
PL (1) PL2508207T3 (es)
PT (1) PT2508207E (es)
RS (1) RS52880B (es)
RU (1) RU2616494C2 (es)
SG (1) SG193453A1 (es)
SI (1) SI2691116T1 (es)
SM (1) SMT201600197B (es)
WO (1) WO2012131018A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2508207T3 (pl) 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy
BR112014031471B1 (pt) * 2012-07-17 2020-12-01 Dow Global Technologies Llc composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem
ES2818110T3 (es) 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
US20170151181A1 (en) * 2014-04-18 2017-06-01 Pfizer Inc. Methods of treating cancers with therapeutic nanoparticles
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US20160106722A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
AU2016298210B2 (en) 2015-07-28 2021-12-09 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
CA3015241A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
CN106511365A (zh) * 2016-12-17 2017-03-22 郑州郑先医药科技有限公司 一种治疗肝硬化的西药组合物
JP7317038B2 (ja) * 2018-03-27 2023-07-28 シンテフ ティーティーオー エイエス がん治療に使用するためのポリ（アルキルシアノアクリレート）ナノ粒子
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310667A (en) 1976-04-22 1982-01-12 Agence Nationale De Valorisation De La Recherche (Anvar) 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
IL165392A0 (en) * 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
JP5201763B2 (ja) * 2007-02-28 2013-06-05 昇一 城武 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2050747A1 (en) 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
AU2008315718A1 (en) * 2007-10-26 2009-04-30 Pfizer Products Inc. Idarubicin for the treatment of lymphoma in a dog
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
PL2508207T3 (pl) 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy

Also Published As

Publication number Publication date
BR112013019105A2 (pt) 2019-04-02
PT2508207E (pt) 2013-07-22
CN105233301A (zh) 2016-01-13
US20140024610A1 (en) 2014-01-23
JP2014503577A (ja) 2014-02-13
RS52880B (en) 2014-02-28
CA2822177A1 (en) 2012-10-04
CY1117868T1 (el) 2017-05-17
HK1192841A1 (zh) 2014-09-05
KR101578273B1 (ko) 2015-12-16
CN103379920A (zh) 2013-10-30
CA2822177C (en) 2016-02-16
ES2424476T3 (es) 2013-10-02
EP2691116A1 (en) 2014-02-05
US9763874B2 (en) 2017-09-19
SI2691116T1 (sl) 2016-10-28
SMT201600197B (it) 2016-08-31
DK2691116T3 (en) 2016-07-04
KR20130114240A (ko) 2013-10-16
US20170333341A1 (en) 2017-11-23
EP2691116B8 (en) 2016-06-01
MY162339A (en) 2017-06-15
ES2577955T3 (es) 2016-07-19
EP2508207B1 (en) 2013-05-08
EP2508207A1 (en) 2012-10-10
MX2013007581A (es) 2013-11-01
DK2508207T3 (da) 2013-07-29
HRP20130702T1 (en) 2013-09-30
RU2013128934A (ru) 2015-01-10
AU2012233666B2 (en) 2014-01-16
SG193453A1 (en) 2013-10-30
HUE028465T2 (en) 2016-12-28
IL227466A (en) 2016-12-29
PL2508207T3 (pl) 2013-09-30
JP5523638B2 (ja) 2014-06-18
HRP20160708T1 (hr) 2016-07-15
IL227466A0 (en) 2013-09-30
RU2616494C2 (ru) 2017-04-17
EP2691116B1 (en) 2016-03-23
AU2012233666A1 (en) 2013-07-11
WO2012131018A1 (en) 2012-10-04
ME02470B (me) 2017-02-20

Similar Documents

Publication Publication Date Title
MX344704B (es) Nanopartículas cargadas con medicamento antitumoral quimioterapéutico.
NZ713868A (en) Treatment of cancer using coenzyme q10 combination therapies
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ717504A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
NZ708506A (en) Methods of treating bladder cancer
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
JO3737B1 (ar) تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
PH12016501407A1 (en) Treatment of neoplasia
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
WO2012158776A3 (en) Combination therapy for treatment of cancer
RU2012123182A (ru) Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
EA201590325A1 (ru) Улучшенные способы лечения рака с пониженной почечной токсичностью
Rodríguez-Romo et al. Outpatient reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia in children.
TH151382A (th) อนุภาคนาโน (nanoparticles) ที่ถูกบรรจุด้วยยาที่ต้านเนื้องอกเคมีบำบัด (chemotherapeutic antitumoral drug)
UA89689U (ru) Способ лечения больных вич/спид-ассоциированным туберкулезом

Legal Events

Date Code Title Description
FG Grant or registration